Cat. #154164
LNCaP androgen-independent cell line
Cat. #: 154164
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Northern Institute For Cancer Research, Newcastle University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: LNCaP androgen-independent cell line
- Cancer: Genitourinary cancer
- Cancers detailed: Human prostate adenocarcinoma
- Research fields: Cancer
- Tool sub type: Continuous
- Parental cell: LNCaP
- Organism: Human
- Disease: Cancer
- Model: Tumour line
- Conditional: No
- Description: LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist. This cell line is the most commonly used for prostate cancer research. The cell line is a clonal population of LNCaP cells grown in steroid-depleted conditions for ~4 months. Cells adapted to growth conditions and are now routinely grown in media lacking testosterone
- Production details: LNCaP cells grown in steroid-depleted conditions for ~4 months
Handling
- Format: Frozen
- Growth medium: RPMI-1640 + 10% FBS
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
